CD38 and neoplasm: Isatuximab is a novel CD38-targeting antibody raised against a different epitope from daratumumab and is differentiated by the direct cytotoxic effect it can induce in tumors, as well as stronger inhibition of the tumor suppressive NADase role of CD38 in vitro [7,8].